



**For immediate release: November 28, 2011**

## **NuCare Medical Systems of Korea Purchases Zecotek's Patented LFS Scintillation Crystals & Arrays**

**Singapore, November 28, 2011 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I)**, a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that its patented LFS scintillation crystals and arrays have been ordered by NuCare Medical Systems of Seoul, Korea. NuCare is known for its innovation in product design and specialized products in the area of nuclear medical imaging.

"We have ordered Zecotek's LFS-7 scintillation crystals for use in a non-destructive assay system and the development of a new positron emission tomography (PET) system," said Dr. Jinhun Joung, Chief Executive Officer NuCare Medical Systems. "The price point, the superior performance and IP stability of the LFS crystals are very attractive to NuCare with the aim of maintaining our international competitiveness in the specialized field of nuclear medical imaging. With Zecotek's assistance we can meet our goal."

"NuCare Medical Imaging has order our LFS-7 crystals and arrays due to their superior performance and competitive pricing," said Dr. Faouzi Zerrouk, Chairman and President of Zecotek. "More and more of organizations are recognizing the competitive advantages of our medical imaging components, crystals and arrays, in bringing unprecedented performance to a wide range of imaging technologies at a competitive cost. We anticipate growing demand for our crystals and have taken steps to ensure a consistent supply and consistent supply of our scintillation crystals."

Zecotek has developed and patented a new class of advanced materials for use in next-generation PET, PET-CT, PET-MRI and other specialized medical imaging scanners. When combined with Zecotek's MAPD solid-state photo detectors, the LFS scintillation crystals allows for medical imaging devices to have higher resolution, enhanced diagnosis, improved patient outcomes, faster patient throughput and lower unit costs. Other medical applications for LFS are in micro-PET detectors, widely used in drug research, and in gamma cameras used for breast and prostate examinations. Non-medical applications include gamma ray detector systems for homeland security, geological surveying, materials analysis, high energy physics and nuclear stockpile monitoring.

-30-

### **About NuCare Medical Systems, Inc.**

NuCare Medical Systems, Inc. is based in Seoul, Korea and provides products in the field of radiation monitoring and nuclear medicine. NuCare medical system core competencies are in various types of NaI(Tl)+PMT based gamma radiation detection/monitoring systems. The products of NuCare are featured with innovative design and concepts that offer superior quality while maintaining favorable price. NuCare's products include digital MCA, thyroid uptake system, well counter, spectroscopic area monitor, TLC scanner, radiation portal monitor, food radiation scanner and more. For more information please visit <http://www.nucaremed.com/nucare/index.html>.



### **About Zecotek**

Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonics technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit [www.zecotek.com](http://www.zecotek.com).

*This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.*

### **For Additional Information Please Contact:**

Zecotek Photonics Inc.  
Michael Minder  
T: (604) 783-8291  
[ir@zecotek.com](mailto:ir@zecotek.com)

CHF Investor Relations  
Julia Clark, Account Manager  
T: (416) 868-1079 x236  
[julia@chfir.com](mailto:julia@chfir.com)

*Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at [www.zecotek.com](http://www.zecotek.com).*